CoChat

Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot

Hampel, Harald, Lista, Simone, Khachaturian, Zaven S. · 2012 · Alzheimer's & Dementia
Cited by 135

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

The aim of this perspective article is to stimulate radical shifts in thinking and foster further discussion on the effective discovery, development, validation, and qualification process of biological markers derived from all available technical modalities that meet the complex conceptual and pathophysiological challenges across all stages of the complex, nonlinear, dynamic, and chronically progressive sporadic Alzheimer's disease (AD). This perspective evaluates the current state of the science regarding a broad spectrum of hypothesis‐driven and exploratory technologies and “markers” as candidates for all required biomarker functions, in particular, surrogate indicators of adaptive to maladaptive and compensatory to decompensatory, reversible to irreversible brain “systems failure.” We stress the future importance of the systems biology (SB) paradigm (next to the neural network paradigm) for substantial progress in AD research. SB represents an integrated and deeper investigation of interacting biomolecules within cells and organisms. This approach has only recently become feasible as high‐throughput technologies and mass spectrometric analyses of proteins and lipids, together with rigorous bioinformatics, have evolved. Existing high‐content data derived from clinically and experimentally derived neural tissues point to convergent pathophysiological pathways during the course of AD, transcending traditional descriptive studies to reach a more integrated and comprehensive understanding of AD pathophysiology, derived systems biomarkers, and “druggable” system nodes. The discussion is continued on the premise that the lack of integration of advanced biomarker technologies and transfertilization from more mature translational research fields (e.g., oncology, immunology, cardiovascular), which satisfy regulatory requirements for an accurate, sensitive, and well‐validated surrogate marker of specific pathophysiological processes and/or clinical outcomes, is a major rate‐limiting factor for the successful development and approval of effective treatments for AD prevention. We consider the conceptual, scientific, and technical challenges for the discovery‐development‐validation‐qualification process of biomarker tools and analytical algorithms for detection of the earliest pathophysiological processes in asymptomatic individuals at elevated risk during preclinical stages of AD. The most critical need for rapid translation of putative markers into validated (performance) and standardized (harmonized standard operating procedures) biomarker tools that fulfill regulatory requirements (qualify for use in treatment trials: e.g., safety, target engagement, mechanism of action, enrichment, stratification, secondary and primary outcome, surrogate outcome) is the availability of a large‐scale worldwide comprehensive longitudinal database that includes the following cohorts: (a) healthy aging, (b) people at elevated risks (genetic/epigenetic/lifestyle/comorbid conditions), and (c) asymptomatic–preclinical/prodromal–mild cognitive impairment/syndromal mild, moderate, or severe AD. Our proposal, as initial strategic steps for integrating markers into future development of diagnostic and therapy trial technologies, is to work toward: (a) creating the essential research and development infrastructure as an international shared resource, (b) building the organizational structure for managing such a multinational shared resource, and (c) establishing an integrated transsectoral multidisciplinary global network of collaborating investigators to help build and use the shared research resource.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2012.05.2116

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Research works printed but not linked: 104

  1. 10.1016/j.pneurobio.2011.09.004 · DOI
  2. 10.1212/WNL.34.7.939 · DOI · Paper page
  3. 10.1016/j.jalz.2011.03.005 · DOI · Paper page
  4. 10.1186/1750-1326-4-19 · DOI · Paper page
  5. 10.1016/j.pneurobio.2011.08.014 · DOI
  6. 10.1007/BF03256398 · DOI
  7. Thomas L, 2007, Labor und diagnose
  8. 10.1007/s12603-009-0036-7 · DOI
  9. 10.1038/nrd3115 · DOI · Paper page
  10. 10.1038/nrd1130 · DOI · Paper page
  11. 10.1067/mcp.2001.113989 · DOI · Paper page
  12. 10.1111/j.1755-5949.2009.00104.x · DOI · Paper page
  13. 10.1016/j.pneurobio.2011.07.004 · DOI · Paper page
  14. 10.1016/j.pneurobio.2011.07.008 · DOI
  15. Bertram L, 2011, The role of genetics for biomarker development in neurodegeneration, Prog Neurobiol, 95, 501, 10.1016/j.pneurobio.2011.09.011 · DOI
  16. 10.1016/j.pneurobio.2011.11.008 · DOI · Paper page
  17. 10.1523/JNEUROSCI.4521-10.2010 · DOI · Paper page
  18. 10.1002/ana.22365 · DOI · Paper page
  19. 10.1016/j.biopsych.2010.05.013 · DOI · Paper page
  20. Hampel H. Amyloid‐β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. J Alzheimers Dis (in press).
  21. 10.1016/j.neurobiolaging.2010.04.013 · DOI · Paper page
  22. 10.1093/brain/awl051 · DOI · Paper page
  23. 10.1148/radiol.10091402 · DOI · Paper page
  24. 10.1016/j.tins.2011.05.005 · DOI · Paper page
  25. 10.1212/WNL.0b013e3182563bbe · DOI · Paper page
  26. 10.1196/annals.1427.007 · DOI · Paper page
  27. 10.1212/01.WNL.0000147469.18313.3B · DOI · Paper page
  28. 10.1212/WNL.0b013e3181b23564 · DOI · Paper page
  29. 10.1212/WNL.0b013e31820af94e · DOI · Paper page
  30. 10.1016/j.pneurobio.2011.11.009 · DOI
  31. 10.1007/s12603-012-0044-x · DOI · Paper page
  32. 10.1007/s12603-012-0021-4 · DOI
  33. 10.1016/j.jalz.2007.08.006 · DOI · Paper page
  34. 10.1016/j.expneurol.2009.09.024 · DOI · Paper page
  35. 10.1602/neurorx.1.2.213 · DOI · Paper page
  36. 10.1016/j.jalz.2011.09.172 · DOI · Paper page
  37. 10.1001/archneurol.2011.183 · DOI · Paper page
  38. 10.1016/S0014-4886(03)00027-X · DOI
  39. 10.1038/mp.2008.84 · DOI · Paper page
  40. 10.1002/ana.20144 · DOI
  41. 10.1212/01.wnl.0000229925.52203.4c · DOI · Paper page
  42. 10.1373/clinchem.2006.066720 · DOI · Paper page
  43. 10.1080/00365510701864610 · DOI · Paper page
  44. 10.3233/JAD-2012-111361 · DOI · Paper page
  45. CLMasters DJSelkoe.Biochemistry of amyloid β‐protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med(in press).
  46. 10.1038/nm.2221 · DOI
  47. 10.1016/j.molmed.2006.10.002 · DOI
  48. 10.1523/JNEUROSCI.4580-03.2004 · DOI · Paper page
  49. 10.3233/JAD-2010-1253 · DOI · Paper page
  50. 10.1016/S0006-8993(99)01146-4 · DOI
  51. 10.1016/S0006-8993(97)01355-3 · DOI
  52. 10.1371/journal.pone.0016032 · DOI · Paper page
  53. 10.1371/journal.pone.0018850 · DOI · Paper page
  54. 10.1002/ana.22448 · DOI · Paper page
  55. 10.1212/WNL.0b013e318248e568 · DOI · Paper page
  56. 10.1007/s00702-003-0065-z · DOI
  57. 10.1602/neurorx.1.2.226 · DOI · Paper page
  58. 10.1038/nm1635 · DOI · Paper page
  59. 10.3233/JAD-2011-111421 · DOI · Paper page
  60. 10.1001/archneurol.2008.565 · DOI · Paper page
  61. 10.1212/WNL.57.12.2243 · DOI
  62. 10.1001/archneur.59.1.71 · DOI · Paper page
  63. 10.1016/S0197-4580(01)00340-2 · DOI · Paper page
  64. 10.1001/archneur.59.6.972 · DOI · Paper page
  65. 10.1002/ana.10272 · DOI · Paper page
  66. 10.1038/nature01325 · DOI · Paper page
  67. 10.1001/archneurol.2010.215 · DOI · Paper page
  68. 10.1007/978-3-0348-8350-4_6 · DOI
  69. 10.1007/s00406-004-0558-2 · DOI
  70. 10.1016/S0304-3940(97)00379-0 · DOI
  71. 10.1016/S0006-8993(97)01355-3 · DOI
  72. 10.1007/s00406-003-0405-x · DOI
  73. 10.1016/j.biopsych.2009.01.032 · DOI
  74. 10.1001/archneurol.2008.530 · DOI · Paper page
  75. 10.1093/brain/awl279 · DOI · Paper page
  76. 10.1371/journal.pone.0028527 · DOI · Paper page
  77. 10.1586/14789450.4.2.227 · DOI · Paper page
  78. 10.1371/journal.pone.0031501 · DOI · Paper page
  79. 10.1016/j.tins.2008.10.003 · DOI
  80. 10.1038/35015709 · DOI · Paper page
  81. 10.1038/nature01510 · DOI · Paper page
  82. 10.1016/j.semcancer.2006.03.005 · DOI · Paper page
  83. Check‐Hayden E, 2008, International genome project launched, Nature, 541, 378, 10.1038/451378b · DOI
  84. 10.1126/science.319.5862.395 · DOI
  85. Gottesman I, 1972, Schizophrenia and genetics: a twin study vantage point
  86. 10.1007/s00406-007-1006-x · DOI
  87. 10.1586/erm.09.42 · DOI
  88. 10.1586/erm.10.48 · DOI · Paper page
  89. 10.1016/j.pneurobio.2010.11.005 · DOI
  90. 10.1038/nrd2006 · DOI · Paper page
  91. Oliver KG, 1998, Multiplexed analysis of human cytokines by use of the FlowMetrix system, Clin Chem, 44, 2057, 10.1093/clinchem/44.9.2057 · DOI · Paper page
  92. 10.1373/clinchem.2004.047084 · DOI · Paper page
  93. 10.1021/pr050080b · DOI · Paper page
  94. 10.1186/alzrt49 · DOI · Paper page
  95. 10.1016/j.biopsych.2010.09.020 · DOI
  96. 10.1016/S1474-4422(10)70030-2 · DOI
  97. 10.1038/nature04209 · DOI · Paper page
  98. 10.18632/aging.100413 · DOI · Paper page
  99. 10.1002/ana.21634 · DOI
  100. 10.2741/2677 · DOI
  101. 10.1002/mas.20338 · DOI
  102. 10.1007/s00401-011-0808-0 · DOI · Paper page
  103. ASKesselheim JKarlawish.Biomarkers unbound — the Supreme Court's ruling on diagnostic‐test patents [published online ahead of print May 23 2012]. N Engl Jdoi:10.1056/NEJMp1204164. · doi:10.1056/nejmp1204164
  104. Hampel H, 2011, Special Issue. Biological markers for neurodegenerative diseases, Prog Neurobiol, 95, 491

Cited by

Metadata

Authors
Hampel, H., Lista, S., & Khachaturian, Z. S.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2012-07
Volume
8
Issue
4
Pages
312-336
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2058267476
Cited by
135
References
58
FWCI
10.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.